P 014
Alternative Names: P-014Latest Information Update: 28 Mar 2024
At a glance
- Originator Kira Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in China
- 28 Mar 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in China
- 16 Nov 2021 Kira Pharmaceuticals plans a clinical trial in Autoimmune disorders and Inflammation in 2022